Lumosa Therapeutics Co., Ltd. (TPEX:6535)
Taiwan
· Delayed Price · Currency is TWD 155.50
+4.00 (2.64%)
Mar 10, 2026, 10:46 AM CST
Lumosa Therapeutics Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 181.59 | 235.49 | 425.25 | 516.85 | 840.32 | Upgrade
|
| Short-Term Investments | 616.74 | 1,117 | 419.06 | 667.67 | 589.89 | Upgrade
|
| Trading Asset Securities | - | - | - | - | 21.89 | Upgrade
|
| Cash & Short-Term Investments | 798.34 | 1,353 | 844.31 | 1,185 | 1,452 | Upgrade
|
| Cash Growth | -40.99% | 60.23% | -28.72% | -18.43% | 14.26% | Upgrade
|
| Accounts Receivable | 12.9 | 20.63 | 12 | 14 | 9.69 | Upgrade
|
| Other Receivables | 11.48 | 19.16 | 18.13 | 17.98 | 17.01 | Upgrade
|
| Receivables | 24.38 | 39.79 | 30.14 | 31.98 | 26.7 | Upgrade
|
| Inventory | 98.78 | 97.78 | 103.91 | 108.68 | 82.39 | Upgrade
|
| Prepaid Expenses | 44.59 | 46.64 | 65.66 | 60.88 | 59.17 | Upgrade
|
| Other Current Assets | 0 | 0.02 | 0.02 | - | 0.13 | Upgrade
|
| Total Current Assets | 966.1 | 1,537 | 1,044 | 1,386 | 1,620 | Upgrade
|
| Property, Plant & Equipment | 14.44 | 19.68 | 27.53 | 7.66 | 13 | Upgrade
|
| Long-Term Investments | 669 | 575.42 | 583.79 | 464.72 | 671.32 | Upgrade
|
| Other Intangible Assets | 0.37 | 0.49 | 0.6 | 26.93 | 43.57 | Upgrade
|
| Other Long-Term Assets | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | Upgrade
|
| Total Assets | 1,650 | 2,133 | 1,656 | 1,886 | 2,349 | Upgrade
|
| Accounts Payable | 1.31 | 1.42 | 1.49 | 12.25 | 14.5 | Upgrade
|
| Accrued Expenses | - | 36.7 | 54.41 | 33.62 | 43.26 | Upgrade
|
| Current Portion of Leases | 6.92 | 4.2 | 4.49 | 4.33 | 5.4 | Upgrade
|
| Current Unearned Revenue | 2.8 | 3.04 | 3.04 | 6.88 | 4.68 | Upgrade
|
| Other Current Liabilities | 120.01 | 155.83 | 156.14 | 158.28 | 156.18 | Upgrade
|
| Total Current Liabilities | 131.04 | 201.18 | 219.58 | 215.36 | 224.03 | Upgrade
|
| Long-Term Leases | - | 4.28 | 8.12 | 0.36 | 6.08 | Upgrade
|
| Total Liabilities | 131.04 | 205.46 | 227.69 | 215.72 | 230.11 | Upgrade
|
| Common Stock | 1,688 | 1,689 | 1,650 | 1,631 | 1,632 | Upgrade
|
| Additional Paid-In Capital | 265.83 | 2,223 | 1,363 | 1,268 | 1,271 | Upgrade
|
| Retained Earnings | -340.54 | -1,919 | -1,494 | -1,256 | -761.44 | Upgrade
|
| Treasury Stock | -56.8 | - | - | - | - | Upgrade
|
| Comprehensive Income & Other | -47.22 | -81.59 | -117.45 | -13.53 | -22.98 | Upgrade
|
| Total Common Equity | 1,509 | 1,912 | 1,401 | 1,630 | 2,119 | Upgrade
|
| Minority Interest | 9.76 | 15.84 | 27.89 | 40.18 | - | Upgrade
|
| Shareholders' Equity | 1,519 | 1,928 | 1,429 | 1,670 | 2,119 | Upgrade
|
| Total Liabilities & Equity | 1,650 | 2,133 | 1,656 | 1,886 | 2,349 | Upgrade
|
| Total Debt | 6.92 | 8.48 | 12.61 | 4.69 | 11.49 | Upgrade
|
| Net Cash (Debt) | 791.42 | 1,344 | 831.7 | 1,180 | 1,441 | Upgrade
|
| Net Cash Growth | -41.13% | 61.64% | -29.51% | -18.10% | 14.89% | Upgrade
|
| Net Cash Per Share | 4.76 | 8.22 | 5.12 | 7.26 | 9.55 | Upgrade
|
| Filing Date Shares Outstanding | 165.65 | 168.9 | 164.97 | 163.1 | 163.15 | Upgrade
|
| Total Common Shares Outstanding | 165.65 | 168.9 | 164.97 | 163.1 | 163.15 | Upgrade
|
| Working Capital | 835.06 | 1,336 | 824.46 | 1,171 | 1,396 | Upgrade
|
| Book Value Per Share | 9.11 | 11.32 | 8.49 | 9.99 | 12.99 | Upgrade
|
| Tangible Book Value | 1,509 | 1,911 | 1,400 | 1,603 | 2,075 | Upgrade
|
| Tangible Book Value Per Share | 9.11 | 11.32 | 8.49 | 9.83 | 12.72 | Upgrade
|
| Machinery | - | 41.95 | 41.5 | 31.82 | 29.53 | Upgrade
|
| Leasehold Improvements | - | 3.21 | 3.21 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.